Which of the following describes a first-line antihistamine regimen for allergic rhinitis in adults?

Study for APEA Management EENT Test with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

Which of the following describes a first-line antihistamine regimen for allergic rhinitis in adults?

Explanation:
The key idea is choosing an antihistamine that effectively relieves allergic rhinitis symptoms with minimal sedation and convenient dosing. For adults, the preferred first-line option are second-generation antihistamines that are nonsedating and typically taken once daily. These drugs work well to reduce sneezing, itching, and rhinorrhea, but they cross the blood-brain barrier far less than older agents, so they cause little to no drowsiness and fewer cognitive side effects. The once-daily dosing also helps with adherence, making it easier to maintain symptom control over time. Diphenhydramine and chlorpheniramine are older, first-generation antihistamines that enter the brain easily and cause noticeable sedation and anticholinergic effects, which is why they’re not favored as first-line choices. A descriptor like long-acting, sedating is inconsistent with the goal of a non-sedating, once-daily regimen. The option that emphasizes once-daily and nonsedating fits the best approach to initial management.

The key idea is choosing an antihistamine that effectively relieves allergic rhinitis symptoms with minimal sedation and convenient dosing. For adults, the preferred first-line option are second-generation antihistamines that are nonsedating and typically taken once daily. These drugs work well to reduce sneezing, itching, and rhinorrhea, but they cross the blood-brain barrier far less than older agents, so they cause little to no drowsiness and fewer cognitive side effects. The once-daily dosing also helps with adherence, making it easier to maintain symptom control over time.

Diphenhydramine and chlorpheniramine are older, first-generation antihistamines that enter the brain easily and cause noticeable sedation and anticholinergic effects, which is why they’re not favored as first-line choices. A descriptor like long-acting, sedating is inconsistent with the goal of a non-sedating, once-daily regimen. The option that emphasizes once-daily and nonsedating fits the best approach to initial management.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy